CMS' Change of Heart: Niaspan will be Covered Under Medicare Part D

The federal government reverses position on Kos' HDL-elevating agent. The decision could have long-term consequences for the evolution of the cholesterol market.

Michael McCaughan

It doesn’t sound like news: Kos Pharmaceuticals Inc. ’s sustained-release niacin brand Niaspan and Upsher-Smith Laboratories Inc. ’s...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Market Access

More from Pink Sheet